Julie Papanek Grant
CIK 1673237 · last filed 2023-03-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DAWN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Director | 795,000 | $21.53 | $17.12M | -$26.77M | 19 | 2023-03-03 |
| PTGX | Director | 2,453,255 | $125.50 | $307.88M | $7.00M | 3 | 2017-05-26 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| DAWN | Direct | 465,000 | 58.5% | 2021-06-02 |
| Grant Family Delaware Trust Agreement See Footnote |
330,000 | 41.5% | 2023-03-03 | |
| Total | 795,000 | |||
| No longer reported | ||||
| The Grant Family Delaware Trust | 463,200 | — | last 2022-07-06 | |
| By Canaan XI, L.P. | 10,735,645 | — | last 2021-06-02 | |
| PTGX | By Canaan X L.P. | 2,453,255 | 100.0% | 2016-08-16 |
| Total | 2,453,255 | |||
Recent Filings · Page 3 of 3
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-09-15 | PTGX | Grant (A) | — | $0 | EDGAR |
| 2016-08-16 | PTGX | Mixed | +2,453,255 | $7.00M | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).